



**To:** Carter BloodCare Customers  
**From:** Hospital Relations  
**Date:** August 4, 2021  
**Re:** COVID-19 Convalescent Plasma (CCP) Inventory and Usage

### Background

On March 16, 2021, Carter BloodCare discontinued the collection of COVID-19 convalescent plasma due to decreased usage along with the end of government funding of the component. Carter BloodCare has maintained a supply of CCP in inventory, and over the last three weeks, usage of CCP has increased significantly which now has resulted in limited inventory of CCP. We continue to import from other blood centers as available. At this time, Carter BloodCare is evaluating resuming the collection of CCP based on the current demand.

### Impact to Client

- Imported CCP can be labeled with new ISBT product codes.
- Resuming collection of CCP locally along with a lack of government assisted funding will result in a fee increase for the component.

### Client Action

- Please ensure that your blood bank system can accept the CCP ISBT product codes, E9802 and E9803.
- Orders will be filled primarily for transfusion.
- Stock orders for CCP will be determined on a case-by-case basis.
- Before Carter BloodCare begins the recruitment and collection process for CCP, **please provide any feedback you have regarding continued use of CCP.**
- Notify stakeholders of the fee increase for CCP. At a minimum these components could carry a \$500 cost.

